Halozyme Therapeutics (HALO) and Cellectis (CLLS) Financial Contrast
Halozyme Therapeutics and Cellectis are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings. Halozyme Therapeutics presently has a consensus target price of $19.75, indicating a potential upside of 14.49%.
from Biotech News
0 Comments